Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein.
Miederer M, Seidl C, Beyer GJ, Charlton DE, Vranjes-Duric S, Comor JJ, Huber R, Nikula T, Apostolidis C, Schuhmacher C, Becker KF, Senekowitsch-Schmidtke R. Miederer M, et al. Among authors: apostolidis c. Radiat Res. 2003 May;159(5):612-20. doi: 10.1667/0033-7587(2003)159[0612:cotrot]2.0.co;2. Radiat Res. 2003. PMID: 12710872
Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.
Seidl C, Schröck H, Seidenschwang S, Beck R, Schmid E, Abend M, Becker KF, Apostolidis C, Nikula TK, Kremmer E, Schwaiger M, Senekowitsch-Schmidtke R. Seidl C, et al. Among authors: apostolidis c. Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):274-85. doi: 10.1007/s00259-004-1653-3. Epub 2004 Oct 2. Eur J Nucl Med Mol Imaging. 2005. PMID: 15791436
Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.
Senekowitsch-Schmidtke R, Schuhmacher C, Becker KF, Nikula TK, Seidl C, Becker I, Miederer M, Apostolidis C, Adam C, Huber R, Kremmer E, Fischer K, Schwaiger M. Senekowitsch-Schmidtke R, et al. Among authors: apostolidis c. Cancer Res. 2001 Apr 1;61(7):2804-8. Cancer Res. 2001. PMID: 11306447
Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.
Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Buchhorn HM, et al. Among authors: apostolidis c. Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):841-9. doi: 10.1007/s00259-006-0311-3. Epub 2007 Jan 6. Eur J Nucl Med Mol Imaging. 2007. PMID: 17206415
Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study.
Autenrieth ME, Seidl C, Bruchertseifer F, Horn T, Kurtz F, Feuerecker B, D'Alessandria C, Pfob C, Nekolla S, Apostolidis C, Mirzadeh S, Gschwend JE, Schwaiger M, Scheidhauer K, Morgenstern A. Autenrieth ME, et al. Among authors: apostolidis c. Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1364-1371. doi: 10.1007/s00259-018-4003-6. Epub 2018 Apr 11. Eur J Nucl Med Mol Imaging. 2018. PMID: 29644393
In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage.
Vandenbulcke K, De Vos F, Offner F, Philippé J, Apostolidis C, Molinet R, Nikula TK, Bacher K, de Gelder V, Vral A, Lahorte C, Thierens H, Dierckx RA, Slegers G. Vandenbulcke K, et al. Among authors: apostolidis c. Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1357-64. doi: 10.1007/s00259-003-1228-8. Epub 2003 Jul 3. Eur J Nucl Med Mol Imaging. 2003. PMID: 12845484
109 results